Chronic Leg Ulceration Associated with Polycythemia Vera Responding to Ruxolitinib (Jakafi®) – Corrected Proof

Abstract: We present the case of a 63-year-old white male with bilateral chronic leg ulcers due to polycythemia vera and hydroxyurea therapy who demonstrated dramatic healing of his wounds in response to ruxolitinib (Jakafi®, Novartis), a novel Janus kinase-1 and -2 inhibitor.

Original post:
Chronic Leg Ulceration Associated with Polycythemia Vera Responding to Ruxolitinib (Jakafi®) – Corrected Proof

Previous post:

Next post: